ARS2 Regulates Nuclear Paraspeckle Formation through 3'-End Processing and Stability of NEAT1 Long Noncoding RNA.


Journal

Molecular and cellular biology
ISSN: 1098-5549
Titre abrégé: Mol Cell Biol
Pays: United States
ID NLM: 8109087

Informations de publication

Date de publication:
30 01 2020
Historique:
received: 16 06 2019
accepted: 12 11 2019
pubmed: 11 12 2019
medline: 9 7 2020
entrez: 11 12 2019
Statut: epublish

Résumé

Nuclear paraspeckle assembly transcript 1 (NEAT1) is a long noncoding RNA that functions as an essential framework of subnuclear paraspeckle bodies. Of the two isoforms (NEAT1_1 and NEAT1_2) produced by alternative 3'-end RNA processing, the longer isoform, NEAT1_2, plays a crucial role in paraspeckle formation. Here, we demonstrate that the 3'-end processing and stability of NEAT1 RNAs are regulated by arsenic resistance protein 2 (ARS2), a factor interacting with the cap-binding complex (CBC) that binds to the m7G cap structure of RNA polymerase II transcripts. The knockdown of ARS2 inhibited the association between NEAT1 and mammalian cleavage factor I (CFIm), which produces the shorter isoform, NEAT1_1. Furthermore, the knockdown of ARS2 led to the preferential stabilization of NEAT1_2. As a result, NEAT1_2 RNA levels were markedly elevated in ARS2 knockdown cells, leading to an increase in the number of paraspeckles. These results reveal a suppressive role for ARS2 in NEAT1_2 expression and the subsequent formation of paraspeckles.

Identifiants

pubmed: 31818879
pii: MCB.00269-19
doi: 10.1128/MCB.00269-19
pmc: PMC6996275
pii:
doi:

Substances chimiques

MALAT1 long non-coding RNA, human 0
NEAT1 long non-coding RNA, human 0
Nuclear Proteins 0
RNA, Long Noncoding 0
RNA, Small Interfering 0
SRRT protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

Mol Cell. 2009 Mar 27;33(6):717-26
pubmed: 19217333
Mol Cell. 2012 Jan 13;45(1):87-98
pubmed: 22244333
Science. 2007 Jun 8;316(5830):1484-8
pubmed: 17510325
Genome Res. 2009 Mar;19(3):347-59
pubmed: 19106332
Nat Rev Genet. 2009 Mar;10(3):155-9
pubmed: 19188922
Front Biosci (Elite Ed). 2015 Jan 01;7:1-41
pubmed: 25553361
Development. 2014 Dec;141(23):4618-27
pubmed: 25359727
J Biol Chem. 2011 Jul 1;286(26):22758-68
pubmed: 21536667
Science. 2005 Sep 2;309(5740):1559-63
pubmed: 16141072
Mol Cell. 2014 Feb 6;53(3):393-406
pubmed: 24507715
Mol Biol Cell. 2010 Nov 15;21(22):4020-7
pubmed: 20881053
Nat Struct Mol Biol. 2013 Dec;20(12):1358-66
pubmed: 24270878
Cell. 2006 Dec 1;127(5):1071
pubmed: 17129789
Mol Cell. 2009 Oct 23;36(2):267-78
pubmed: 19854135
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19202-7
pubmed: 23129630
Mol Cell. 2010 Sep 24;39(6):925-38
pubmed: 20797886
Mol Cell Biol. 2009 Sep;29(17):4729-41
pubmed: 19546234
Cell. 2009 Jul 23;138(2):328-39
pubmed: 19632182
EMBO J. 2012 Oct 17;31(20):4020-34
pubmed: 22960638
Mol Cell. 2011 Sep 16;43(6):904-14
pubmed: 21925379
Cell Rep. 2012 Jun 28;1(6):753-63
pubmed: 22813749
Cell. 2000 Apr 14;101(2):187-98
pubmed: 10786834
Cell Prolif. 2016 Aug;49(4):471-5
pubmed: 27339553
Genes Dev. 2012 Nov 1;26(21):2392-407
pubmed: 23073843
PLoS Genet. 2013;9(10):e1003893
pubmed: 24146636
Nucleic Acids Res. 2017 Sep 29;45(17):10229-10241
pubmed: 28973446
J Virol. 2017 May 26;91(12):
pubmed: 28356525
Cell. 1994 Aug 26;78(4):657-68
pubmed: 8069914
Science. 2012 Mar 30;335(6076):1643-6
pubmed: 22461616
Nat Struct Mol Biol. 2014 Jul;21(7):633-40
pubmed: 24952594
Nat Cell Biol. 2011 Jan;13(1):95-101
pubmed: 21170033
Nat Med. 2016 Aug;22(8):861-8
pubmed: 27376578
Nat Struct Mol Biol. 2013 Dec;20(12):1367-76
pubmed: 24270879
Mol Cell. 2016 Nov 3;64(3):520-533
pubmed: 27871484
Cell Rep. 2017 Mar 14;18(11):2635-2650
pubmed: 28297668
EMBO J. 2017 May 15;36(10):1447-1462
pubmed: 28404604
Mol Cell. 2018 Jun 21;70(6):1038-1053.e7
pubmed: 29932899
Exp Cell Res. 2010 Oct 15;316(17):2723-30
pubmed: 20541545
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2525-30
pubmed: 19188602

Auteurs

Mitsuhiro Machitani (M)

Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan mmachita@ncc.go.jp hitoohno@infront.kyoto-u.ac.jp.
Division of Cancer Stem Cell, National Cancer Center Research Institute, Tokyo, Japan.

Ichiro Taniguchi (I)

Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.

Mutsuhito Ohno (M)

Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan mmachita@ncc.go.jp hitoohno@infront.kyoto-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH